 The markets skepticism around Aptinyx Incs NASDAQ: APTX post-traumatic stress disorder PTSD candidate appears overdone, according to Piper Sandler. The Aptinyx Analyst: Christopher Raymond initiated coverage of Aptinyx with an Overweight rating and a price target of 10. 